3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
18
Melanoma
16
Triple Negative Breast Neoplasms
13
Colorectal Neoplasms
11
Neoplasms
9
Neoplasm Metastasis
9
Squamous Cell Carcinoma of Head and Neck
7
Pancreatic Neoplasms
7
Carcinoma, Renal Cell
7
Stomach Neoplasms
6
Lymphoma
6
Uterine Cervical Neoplasms
5
Ovarian Neoplasms
5
Lung Neoplasms
4
Liver Neoplasms
4
Head and Neck Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Esophageal Neoplasms
4
Endometrial Neoplasms
4
Breast Neoplasms
4
Small Cell Lung Carcinoma
3
Sarcoma
3
Nasopharyngeal Carcinoma
3
Colonic Neoplasms
3
Carcinoma, Hepatocellular
3
Advanced Solid Tumor
3
Solid Tumors
2
Solid Tumor, Adult
2
Recurrence
2
Rectal Neoplasms
2
Interventions
Ipilimumab
9
pembrolizumab
6
Nivolumab
4
tremelimumab
3
Paclitaxel
3
Carboplatin
3
spartalizumab
2
lenvatinib
2
durvalumab
2
Doxorubicin
2
Bevacizumab
2
trastuzumab deruxtecan
1
tilsotolimod
1
tebentafusp
1
osimertinib
1
eribulin
1
envafolimab
1
cemiplimab
1
balstilimab
1
Vemurafenib
1
Vascular Endothelial Growth Factor A
1
Standard of Care
1
Pemetrexed
1
Oxaliplatin
1
Docetaxel
1
Cisplatin
1
Capecitabine
1
Axitinib
1
Antibodies, Bispecific
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Diabetes Mellitus, Insulin-Dependent, 12
×
spartalizumab
×
Clear all
NCT05751928
2025-07-08
NEO-MIMAJOR
Biocad
Phase 3
Active not recruiting
411 enrolled
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts